Intellia Therapeutics Inc.

In News

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM - Intellia Therapeutics

Intellia Therapeutics - Mar 02, 2026

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat

MarketBeat - Mar 31, 2026

Intellia Therapeutics, Inc. (NTLA): A Bull Case Theory - Yahoo Finance

Yahoo Finance - Feb 28, 2026

Intellia Therapeutics to resume dosing of gene therapy in Phase III trial - Clinical Trials Arena

Clinical Trials Arena - Jan 28, 2026

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN - Intellia Therapeutics

Intellia Therapeutics - Jan 27, 2026

Baird Updates Intellia Therapeutics, Inc. (NTLA)’s Financial Model Following Nex-Z Clinical Hold Removal - Yahoo Finance

Yahoo Finance - Feb 02, 2026

Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates - Intellia Therapeutics

Intellia Therapeutics - Nov 06, 2025

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates - Intellia Therapeutics

Intellia Therapeutics - Feb 19, 2026

Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Intellia Therapeutics

Intellia Therapeutics - Jan 07, 2026

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) - Intellia Therapeutics

Intellia Therapeutics - Oct 27, 2025

Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy - Intellia Therapeutics

Intellia Therapeutics - Nov 10, 2025

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy - Intellia Therapeutics

Intellia Therapeutics - Sep 25, 2025

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment